ArticlePloS one2020
Clinical and molecular characterization of COVID-19 hospitalized patients.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis.The American journal of emergency medicine · 2021Pooled it
- Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research.European journal of human genetics : EJHG · 2021Trial
- Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features.Frontiers in genetics · 2024Article
- Predictive Role of Cytokine and Adipokine Panel in Hospitalized COVID-19 Patients: Evaluation of Disease Severity, Survival and Lung Sequelae.International journal of molecular sciences · 2023Article
- Whole exome sequencing identifies a rare variant in MAS1 gene in a subject with lethal COVID-19.Gene reports · 2022Article
- Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severity.Cell systems · 2022Article
- Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis.Cytokine · 2022Article
- Informed Consent and Protection of Personal Data in Genetic Research on COVID-19.Healthcare (Basel, Switzerland) · 2022Review
- Whole Exome Sequencing Identifies a Rare Mutation in NACAD as a Possible Cause of COVID Orchitis in Brothers.Urology · 2022Article
- Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review.Frontiers in pharmacology · 2022Article
- Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity.Human genetics · 2022Article
- Severe COVID-19 in Hospitalized Carriers of SingleJournal of personalized medicine · 2021Article
- Prognostic bioindicators in severe COVID-19 patients.Cytokine · 2021Article
- Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome.Journal of personalized medicine · 2021Article
- The Role of Immunogenetics in COVID-19.International journal of molecular sciences · 2021Review
- COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine.Mayo Clinic proceedings · 2021Review
- ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population.European journal of human genetics : EJHG · 2020Article
- Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank.PloS one · 2020Article
- Efficacy of Licorice as Adjunctive Therapy in Critically Ill Patients with COVID-19: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical and molecular characterization by Whole Exome Sequencing (WES) is reported in 35 COVID-19 patients attending the University Hospital in Siena, Italy, from April 7 to May 7, 2020. Eighty percent of patients required respiratory assistance, half of them being on mechanical ventilation. Fiftyone percent had hepatic involvement and hyposmia was ascertained in 3 patients. Searching for common genes by collapsing methods against 150 WES of controls of the Italian population failed to give straightforward statistically significant results with the exception of two genes. This result is not unexpected since we are facing the most challenging common disorder triggered by environmental factors with a strong underlying heritability (50%). The lesson learned from Autism-Spectrum-Disorders prompted us to re-analyse the cohort treating each patient as an independent case, following a Mendelian-like model. We identified for each patient an average of 2.5 pathogenic mutations involved in virus infection susceptibility and pinpointing to one or more rare disorder(s). To our knowledge, this is the first report on WES and COVID-19. Our results suggest a combined model for COVID-19 susceptibility with a number of common susceptibility genes which represent the favorite background in which additional host private mutations may determine disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.